1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 61-70 of 166 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Argon plasma coagulation therapy versus topical formalin for intractable rectal bleeding and anorectal dysfunction after radiation therapy for prostate carcinomaYeoh, E.; Tam, W.; Schoeman, M.; Moore, J.; Thomas, M.; Botten, R.; Di Matteo, A.
2013Nationwide trends in the incidence of acute myocardial infarction in Australia, 1993-2010Wong, C.; Sun, M.; Lau, D.; Brooks, A.; Sullivan, T.; Worthley, M.; Roberts-Thomson, K.; Sanders, P.
2013The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumorsRosen, L.; Lipton, L.; Price, T.; Belman, N.; Boccia, R.; Hurwitz, H.; Stephenson Jr, J.; Wirth, L.; McCoy, S.; Hei, Y.; Hsu, C.; Tebbutt, N.
2013Dissociation between severity of takotsubo cardiomyopathy and presentation with shock or hypotensionChong, C.; Neil, C.; Nguyen, T.; Stansborough, J.; Law, G.; Singh, K.; Horowitz, J.
2013Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progressionButler, M.; Ricciardelli, C.; Tilley, W.; Hickey, T.
2012Human bone material characterization: integrated imaging surface investigation of male fragility fracturesZoehrer, R.; Perilli, E.; Kuliwaba, J.; Shapter, J.; Fazzalari, N.; Voelcker, N.
2013Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLBranford, S.; Yeung, D.; Ross, D.; Prime, J.; Field, C.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Sullivan, B.; Briggs, N.; Hertzberg, M.; Seymour, J.; Reynolds, J.; Hughes, T.
2013GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutationsPerugini, M.; Iarossi, D.; Kok, C.; Cummings, N.; Diakiw, S.; Brown, A.; Danner, S.; Bardy, P.; To, L.; Wei, A.; Lewis, I.; D'Andrea, R.
2015Frailty in nursing homes: the FRAIL-NH scaleKaehr, E.; Visvanathan, R.; Malmstrom, T.K.; Morley, J.E.
2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerPrice, T.; Bruhn, M.; Lee, C.; Hardingham, J.; Townsend, A.; Mann, K.; Simes, J.; Weickhardt, A.; Wrin, J.; Wilson, K.; Gebski, V.; Van Hazel, G.; Robinson, B.; Cunningham, D.; Tebbutt, N.

Discover